Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Does the Canadian Federal Gov listen to the experts
View:
Post by mdjbrown on Apr 07, 2024 4:13pm

Does the Canadian Federal Gov listen to the experts

in the budget on the April 16, 2023?

In March, the federal government's expert panel reviewing the Cannabis Act made recommendations in various areas, including medical cannabis.”

“The panel's recommendations address some of the other hurdles Fitzcharles identified, including effectiveness and high cost. The panel is recommending:
  • Allowing cannabis product sales in pharmacies to people with medical authorization.
  • Removing the excise tax from medical cannabis.
  • Supporting clinical guidance documents for health-care professionals on medical use of cannabis.”
https://www.cbc.ca/news/health/second-opinion-medical-cannabis-1.7162603
Comment by mdjbrown on Apr 07, 2024 4:27pm
typo - April 16, 2024?
Comment by QContinuum1 on Apr 07, 2024 5:21pm
The idiots are not going to listen.  The best we can hope for is another panel to study I'm afraid. Here's hoping though.
Comment by Starkicker on Apr 07, 2024 5:49pm
I'm optimistic about the how the feds respond to the recommendations. I think they'll drop the excise tax for medical marijuana but only reduce it for recreational. They have to meet producers somewhere in the middle, especially since  it was recommended the 10mg THC limit be kept, which wasn't surprising. Still, I think they'll loosen the noose.
Comment by subaru1i on Apr 07, 2024 7:25pm
mdjbrown...some of those points, especially 1 and 3 apply to pharma appliations imho.  The second bullet point would also benefit LABS as a licensed pharmaceutical site for cannabis.    Cost advantage???????   Preliminary math, as a flower grower that may also produce oils for recreational may have to pay a higer excise tax compared to LABS within the pharma/medical ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities